安旭生物
(688075)
| 流通市值：48.14亿 | | | 总市值：48.14亿 |
| 流通股本：1.27亿 | | | 总股本：1.27亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 403,268,418.25 | 248,156,721.31 | 129,406,701.97 | 503,357,076.78 |
| 营业收入 | 403,268,418.25 | 248,156,721.31 | 129,406,701.97 | 503,357,076.78 |
| 二、营业总成本 | 390,136,270.04 | 233,333,906.74 | 112,894,368.8 | 442,709,355.79 |
| 营业成本 | 233,453,244.12 | 146,855,587.18 | 74,913,346.43 | 290,445,148.75 |
| 税金及附加 | 3,961,441.87 | 2,236,581.63 | 1,996,951.09 | 8,559,858.24 |
| 销售费用 | 33,962,155.78 | 22,695,278.78 | 8,524,969.77 | 42,834,420.98 |
| 管理费用 | 35,038,148.2 | 22,295,293.34 | 10,862,380.1 | 66,532,117.54 |
| 研发费用 | 77,098,514.21 | 49,673,727.89 | 19,840,217.39 | 105,274,988.63 |
| 财务费用 | 6,622,765.86 | -10,422,562.08 | -3,243,495.98 | -70,937,178.35 |
| 其中:利息费用 | 31,169.43 | - | - | - |
| 其中:利息收入 | -3,265,415.53 | - | - | - |
| 加:公允价值变动收益 | 25,393,515.39 | 16,387,983.09 | 6,095,879.37 | -54,801,692.97 |
| 加:投资收益 | 87,579,132.86 | 74,824,963.86 | 38,691,313.65 | 140,106,777.14 |
| 资产处置收益 | 4,512,279.88 | 4,624,293.69 | -175,791.22 | 7,162,046.65 |
| 资产减值损失(新) | -1,317,472.93 | -1,317,472.93 | 230,121.79 | -23,966,156.66 |
| 信用减值损失(新) | 124,743.78 | 124,743.78 | - | 273,692.25 |
| 其他收益 | 14,581,342.75 | 14,514,754.88 | 13,159,386.79 | 38,061,974.23 |
| 营业利润平衡项目 | 0 | 0.01 | 0 | 0 |
| 四、营业利润 | 144,005,689.94 | 123,982,080.95 | 74,513,243.55 | 167,484,361.63 |
| 加:营业外收入 | 130,751.08 | 82,827.4 | 49,952.16 | 165,168.17 |
| 减:营业外支出 | 129,878.12 | 99,022.19 | 237.72 | 23,832,570.99 |
| 利润总额平衡项目 | 0 | -0.01 | 0 | 0 |
| 五、利润总额 | 144,006,562.9 | 123,965,886.15 | 74,562,957.99 | 143,816,958.81 |
| 减:所得税费用 | 8,258,272.26 | 8,497,551.64 | 4,228,237.87 | 2,852,149.4 |
| 六、净利润 | 135,748,290.64 | 115,468,334.51 | 70,334,720.12 | 140,964,809.41 |
| 持续经营净利润 | 135,748,290.64 | 115,468,334.51 | 70,334,720.12 | 140,964,809.41 |
| 归属于母公司股东的净利润 | 135,783,697.44 | 115,319,011.32 | 70,190,798.47 | 141,553,680.39 |
| 少数股东损益 | -35,406.8 | 149,323.19 | 143,921.65 | -588,870.98 |
| (一)基本每股收益 | 1.07 | 0.91 | 0.55 | 1.11 |
| (二)稀释每股收益 | 1.07 | 0.91 | 0.55 | 1.11 |
| 八、其他综合收益 | 7,639,053.23 | 924,340.6 | 35,730.24 | -157,052.72 |
| 归属于母公司股东的其他综合收益 | 7,639,053.23 | 924,340.6 | 35,730.24 | -157,052.72 |
| 九、综合收益总额 | 143,387,343.88 | 116,392,675.11 | 70,370,450.36 | 140,807,756.69 |
| 归属于母公司股东的综合收益总额 | 143,422,750.68 | 116,243,351.92 | 70,226,528.71 | 141,396,627.67 |
| 归属于少数股东的综合收益总额 | -35,406.8 | 149,323.19 | 143,921.65 | -588,870.98 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |